// Biotech and Pharma Therapeutics
CVS Health Exec: We Need a Better Definition of What Good Looks Like in Behavioral Health
November 26, 2025 / behavioral health quality / mental health outcomes / CVS Health psychiatry / value-based care / policy mental health
CVS Health’s Dr. Taft Parsons calls for policy-driven standards to define and measure quality in behavioral health, shifting from task completion to patient outcomes—critical for advancing access, care consistency, and value-based mental health models.
Did Pfizer Just Say “Checkmate” to Novo Nordisk?
November 26, 2025 / Pfizer weight loss / obesity drug market / danuglipron trial halted / Novo Nordisk competition / metabolic therapeutics race
Pfizer, despite halting development of its weight loss pill danuglipron due to safety concerns, signals continued interest in the $100B obesity drug market, potentially challenging leaders Novo Nordisk and Eli Lilly in the evolving metabolic therapeutics space.
In letter to Makary, biotech CEOs push for FDA stability and say volatility threatens US innovation
November 21, 2025 / FDA regulatory stability / biotech innovation risk / clinical trial delays / drug development policy / U.S. biomedical leadership
Biotech CEOs urge FDA leadership to restore regulatory consistency, warning that volatility, staff attrition, and shifting standards risk undermining U.S. innovation, increasing costs, and driving clinical trials abroad. Stability is vital to support early-stage drug development and global competitiveness.
Sarepta shares positive safety update on DM1 asset as Arrowhead snares $200M milestone
November 24, 2025 / SRP-1003 DM1 safety / siRNA muscle therapy / Sarepta Arrowhead deal / TRiM platform RNA / myotonic dystrophy drug
Sarepta reported a favorable safety review for SRP-1003, its siRNA therapy for DM1, enabling continued dose escalation and triggering a $200M milestone payment to Arrowhead. The TRiM platform’s safety profile boosts confidence amid past setbacks in oligonucleotide therapies.
Top five biotech clusters in India: Investment hubs, government incentives & growth
November 25, 2025 / India biotech clusters / vaccine biosimilar innovation / biotech investment hubs / government biotech incentives / biopharma growth India
India’s biotech sector is rapidly expanding, with major innovation hubs in Hyderabad, Bengaluru, Mumbai–Pune, Ahmedabad–Vadodara, and Chennai. Supported by government incentives and infrastructure, these clusters drive advances in vaccines, biosimilars, biologics, and digital health, attracting global investment.
// 4th Industrial Revolution
AI tools can ease documentation burden and reduce physician burnout
November 26, 2025 / AI medical scribes / physician burnout reduction / clinical documentation tools / healthcare AI adoption / UCLA AI trial
A UCLA Health trial found that AI scribe tools like Nabla can significantly reduce physician documentation time and modestly improve burnout scores. While promising, accuracy concerns and occasional clinical errors highlight the need for ongoing oversight and refinement.
Hyro Raises $45M Strategic Growth Round to Accelerate AI Agent Adoption in Healthcare
November 26, 2025 / healthcare AI agents / patient access technology / EHR integration tools / AI healthcare investment / digital health automation
Hyro raised $45M to expand its AI agent platform tailored for healthcare workflows. Its voice and chat tools integrate with EHRs, streamline patient access, and reduce staff burden, addressing critical challenges in operational efficiency and care coordination.
AI Can Improve Bedside Manner, Training Healthcare’s Human Skills
November 26, 2025 / AI soft skills training / empathy in healthcare / patient communication tools / AI medical education / human-centered care
AI is now being used to train healthcare professionals in soft skills like empathy and communication—critical yet underdeveloped areas that directly impact patient outcomes. This marks a shift from AI’s traditional use in diagnostics to enhancing human-centered care.
AI model outperforms breast density assessment in breast cancer risk stratification
November 26, 2025 / AI breast cancer risk / mammogram risk model / breast density comparison / Clairity Breast AI / imaging-based prediction
A new AI model, Clairity Breast, outperforms traditional breast density assessments in stratifying five-year breast cancer risk. Trained on over 400,000 mammograms, it enables earlier, more precise risk prediction based solely on imaging, independent of genetics or family history.
AI-powered tool improves object detection for visually impaired users
November 25, 2025 / AI visual impairment aid / NaviSense object detection / real-time assistive tech / vision language models / accessibility smartphone app
Penn State researchers developed NaviSense, an AI-powered app using LLMs and VLMs to enhance real-time object detection for visually impaired users. The tool responds to voice prompts, improving independence, accuracy, and user experience without needing preloaded object models.
// Business & Markets
Tasso, Neurogen Biomarking partner to expand at-home Alzheimer’s testing
November 26, 2025 / at-home Alzheimer’s testing / blood biomarker analysis / cognitive health access / needle-free diagnostics / virtual neurology care
Neurogen Biomarking and Tasso have partnered to enable at-home Alzheimer’s testing using needle-free blood collection. Their integrated model—combining biomarker analysis, digital cognitive assessments, and virtual neurology consultations—aims to accelerate diagnosis and expand access, especially in underserved communities.
PwC and AWS team up for revenue cycle innovation
November 26, 2025 / healthcare revenue cycle / AI billing automation / PwC AWS partnership / claims denial prevention / patient financial experience
PwC and AWS are partnering to modernize revenue cycle management in healthcare using AI and cloud infrastructure. The collaboration aims to improve billing, claims, and reimbursement processes, addressing workforce shortages and rising costs while enhancing patient financial experiences.
Medicare unveils price reductions for 15 drugs, including Novo’s semaglutide
November 26, 2025 / Medicare drug pricing / semaglutide price cuts / CMS IRA savings / Ozempic Wegovy discount / prescription cost reduction
CMS announced significant Medicare price reductions for 15 high-cost drugs, including semaglutide (Ozempic, Wegovy), under the Inflation Reduction Act. Slated for 2027, these cuts aim to lower patient costs, reduce Medicare spending, and improve access to critical therapies.
Kelun, Merck tout ADC as potential first-line treatment in lung cancer
November 25, 2025 / TROP2 ADC lung cancer / sac-TMT Keytruda combo / NSCLC first-line therapy / Merck Kelun partnership / antibody drug conjugate
Kelun and Merck’s TROP2-targeting ADC, sacituzumab tirumotecan (sac-TMT), combined with Keytruda, improved progression-free survival in PD-L1+ NSCLC, marking the first ADC-checkpoint inhibitor combo to succeed as a first-line therapy—potentially transforming lung cancer treatment strategies.
FamilyWell Health Lands $8M to Grow Women’s Mental Health Support
November 25, 2025 / women’s mental health / perinatal menopause care / virtual behavioral health / FamilyWell Health funding / integrated mental healthcare
FamilyWell Health raised $8M to expand its integrated virtual mental health services for women, spanning fertility through menopause. The platform partners with women’s health providers and offers insurer-covered care, targeting anxiety, depression, and other challenges across life stages.
// Legal & Regulatory
Otsuka gains approval for first-of-its-kind treatment against rare kidney disease
November 26, 2025 / IgA nephropathy treatment / Voyxact FDA approval / APRIL protein inhibitor / rare kidney disease / sibeprenlimab injection
The FDA granted accelerated approval to Otsuka’s Voyxact (sibeprenlimab), the first APRIL-targeting injectable for IgA nephropathy. This self-administered therapy significantly reduces proteinuria and offers a novel mechanism for managing this progressive autoimmune kidney disease.
FDA clears reformulated ranitidine for US return
November 26, 2025 / ranitidine FDA approval / NDMA-free formulation / acid reflux treatment / H2 blocker safety / VKT Pharma ranitidine
The FDA has approved a reformulated version of ranitidine by VKT Pharma, addressing NDMA impurity concerns. With enhanced safety measures, the H2 blocker returns after five years, offering renewed treatment access for acid-related conditions.
FDA nod for Sun Pharma’s Unloxcyt in mCSCC or laCSCC
November 26, 2025 / Unloxcyt FDA approval / cosibelimab CSCC treatment / Sun Pharma oncology / metastatic skin cancer / checkpoint inhibitor update
The FDA approved an updated label for Sun Pharma’s Unloxcyt (cosibelimab-ipdl) for metastatic or locally advanced cutaneous squamous cell carcinoma, reflecting long-term response data. The drug was acquired through Sun’s $355M takeover of Checkpoint Therapeutics.
RapidAI Secures FDA Clearance for Five New Deep Clinical AI Modules, Expanding Enterprise Imaging Platform
November 26, 2025 / RapidAI FDA clearance / deep clinical AI / radiology workflow automation / stroke imaging tools / vascular AI modules
RapidAI received FDA clearance for five new imaging modules enhancing its Enterprise Platform with deep clinical AI. These tools support neurologic and vascular care by automating measurements, improving precision, and reducing radiologist workload across acute and long-term patient management.
AZ’s Imfinzi expands perioperative prowess into early-stage stomach cancer with FDA nod
November 25, 2025 / Imfinzi / perioperative stomach cancer / FDA approval / gastric cancer immunotherapy / FLOT chemotherapy combo
The FDA has approved AstraZeneca’s Imfinzi for perioperative use in early-stage gastric and gastroesophageal junction cancers, making it the first immunotherapy indicated for treatment before and after surgery, significantly improving survival outcomes when combined with FLOT chemotherapy.
// Research & Development
AstraZeneca Notches Another Indication for Imfinzi, Pushing PD-L1 Blocker Into Stomach Cancer
November 26, 2025 / Imfinzi approval / gastric cancer immunotherapy / perioperative treatment / PD-L1 inhibitor / AstraZeneca oncology
The FDA has approved AstraZeneca’s Imfinzi as the first perioperative immunotherapy for resectable gastric and gastroesophageal junction cancers. Combined with FLOT chemotherapy, Imfinzi significantly reduced recurrence and mortality risk, marking a major advance in early-stage stomach cancer treatment.
New study shows rheumatoid arthritis begins long before symptoms
November 26, 2025 / rheumatoid arthritis / early detection / immune dysregulation / autoimmune disease / epigenetic changes
A new study reveals rheumatoid arthritis begins years before symptoms, showing early immune dysfunction, widespread inflammation, and epigenetic changes in antibody-positive individuals—suggesting the body primes for autoimmune attack well before joint damage occurs.
Stanford’s new cell therapy cures type 1 diabetes in mice
November 26, 2025 / type 1 diabetes / stem cell therapy / immune tolerance / islet transplant / autoimmune treatment
Stanford researchers cured or prevented Type 1 diabetes in mice using combined blood stem cell and islet cell transplants, creating a hybrid immune system that halts autoimmune attacks without immunosuppression—paving the way for human trials and broader autoimmune applications.
ASTP/ONC offers updated HTI-1 compliance date discretion
November 26, 2025 / HTI-1 compliance / health IT regulations / ONC enforcement discretion / interoperability standards / algorithm transparency
ASTP and ONC have extended HTI-1 compliance deadlines due to the government shutdown, offering enforcement discretion until March 1, 2026. The delay supports health IT developers—especially smaller vendors—facing certification challenges tied to interoperability, algorithm transparency, and data exchange.
CMS covers cardiac ablation in ambulatory surgery centers
November 26, 2025 / cardiac ablation / Medicare reimbursement / ambulatory surgery centers
CMS has approved Medicare reimbursement for cardiac catheter ablation procedures in ambulatory surgery centers (ASCs), potentially increasing access, lowering costs, and expanding procedure volumes—benefiting major device makers like Abbott, Boston Scientific, Johnson & Johnson, and Medtronic.
// Politics
White House hits pause on EO that sought to preempt state AI laws
November 25, 2025 / AI regulation / Genesis Mission / federal preemption / artificial intelligence / healthcare policy
The White House paused a proposed executive order that would let the attorney general challenge state AI laws, amid backlash over states’ rights to regulate AI. Simultaneously, a new federal initiative, The Genesis Mission, aims to accelerate AI innovation for national challenges.
OIG report finds Medicare overpaying for CGMs and supplies
November 26, 2025 / Medicare overpayment / CGM reimbursement / diabetes monitoring costs / CMS competitive bidding / glucose monitor pricing
An OIG report found Medicare overpaid by $377M for continuous glucose monitors (CGMs) and supplies, urging CMS to reduce payments through competitive bidding or “inherent reasonableness.” CMS agrees and is considering a monthly rental model and stricter billing oversight.
Lawmakers propose Medicare reimbursement pathway for AI devices
November 26, 2025 / AI reimbursement / Medicare coverage / medical device policy / algorithm-based healthcare / bipartisan health legislation
Bipartisan lawmakers introduced a bill to establish a Medicare reimbursement pathway for AI-driven medical devices, aiming to provide five years of cost-based reimbursement. The proposal seeks to promote access and improve outcomes through clearer payment policies.
Trump administration quietly unveils new round of Medicare-negotiated drug prices
November 25, 2025 / Medicare drug pricing / Inflation Reduction Act / negotiated drug savings / Trump administration healthcare / CMS drug costs
The Trump administration released Medicare-negotiated prices for 15 drugs, claiming $8.5 billion in savings—a 36% reduction from prior costs. Officials emphasized improved outcomes under their approach to the Inflation Reduction Act’s drug pricing provisions.
US commission recommends federal research revamp to avoid losing global biotech edge
November 25, 2025 / biotech innovation strategy / federal research reform / AI scientific funding / U.S. biotechnology leadership / NSCEB policy recommendations
The National Security Commission on Emerging Biotechnology urges a federal research overhaul to sustain U.S. biotech leadership, recommending streamlined funding, AI integration, and collaborative innovation to counter global competition, especially from China.